Innoviva, Inc. is a high risk Pharmaceuticals company based in the United States that focuses on innovative healthcare assets. With a Risk Rating Score of 30.2, Innoviva's portfolio consists of royalties and key assets in critical care and infectious disease. The company offers a range of products including Relvar/Breo/Ellipta, Anoro, Trelegy, and more. Innoviva is committed to ESG practices, prioritizing environment, sustainability, and governance in its operations.